TESARO Summarizes TSR-042 Clinical Data Presented at AACR
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Tesoro (TSRO) Data Supportive of Future Combos - Cowen
April 16, 2018 12:45 PM EDTCowen analyst Boris Peaker reiterated a Market Perform rating and $66 price target on Tesaro (NASDAQ: TSRO) after the company reported MSI-H endometrial and NSCLC expansion cohort data for TSR-042 (anti-PD-1 mAb) at AACR.
"Response rates of 46.7% and 29.2%, respectively, appear competitive in these two... More
